Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA) has a beta of 1.07. The stock’s Relative Strength Index (RSI) is 66.28, with weekly volatility at 4.88% and ATR at 1.58. The DRNA stock’s 52-week price range has touched low of $16.50 and a $33.78 high. Its shares traded higher over the last trading session, gaining 2.85% on 06/10/21. The shares fell to a low of $32.11 before closing at $33.56. Intraday shares traded counted 0.5 million, which was 31.62% higher than its 30-day average trading volume of 724.29K. DRNA’s previous close was $32.63 while the outstanding shares total 76.26M.
Investors have identified the Biotechnology company Dicerna Pharmaceuticals Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $2.53 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Dicerna Pharmaceuticals Inc. (DRNA) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 594.5 million total, with 182.15 million as their total liabilities.
DRNA were able to record -30.08 million as free cash flow during the 08/12/2021 quarter of the year, this saw their quarterly net cash flow reduce by 32.34 million. In cash movements, the company had a total of -26.7 million as operating cash flow.
Potential earnings growth for Dicerna Pharmaceuticals Inc. (DRNA)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the 08/12/2021 quarter of the year, Dicerna Pharmaceuticals Inc. recorded a total of 47.6 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 28.52% coming in sequential stages and their sales for the 08/12/2021 quarter increasing by 13.96%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 47.6 million trying to sell their products during the last quarter, with the result yielding a gross income of 76.71 million. This allows shareholders to hold on to 76.26M with the recently reported earning now reading -0.39 cents per share. This is a figure that compared to analyst’s prediction for their 08/12/2021 (-0.39 cents a share).
Having a look at the company’s valuation, the company is expected to record -1.07 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on DRNA sounds very interesting.
Is the stock of DRNA attractive?
In related news, Chief Scientific Ofr., EVP R&D, Brown Bob D sold 10,000 shares of the company’s stock in a transaction that recorded on Jun 07. The sale was performed at an average price of 33.00, for a total value of 330,000. As the sale deal closes, the Chief Scientific Ofr., EVP R&D, Brown Bob D now sold 8,312 shares of the company’s stock, valued at 257,078. Also, Chief Human Resources Officer, Paglia Regina M. sold 4,431 shares of the company’s stock in a deal that was recorded on Jun 01. The shares were price at an average price of 30.94 per share, with a total market value of 137,078. Following this completion of acquisition, the Chief Human Resources Officer, Paglia Regina M. now holds 4,431 shares of the company’s stock, valued at 134,192. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.10%.
11 out of 11 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on Dicerna Pharmaceuticals Inc.. 0 analysts has assigned a Sell rating on the DRNA stock. The 12-month mean consensus price target for the company’s shares has been set at $39.67.